AD-109 is under clinical development by Apnimed and currently in Phase III for Obstructive Sleep Apnea. According to GlobalData, Phase III drugs for Obstructive Sleep Apnea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AD-109’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AD-109 overview
Atomoxetine in combination with oxybutynin (AD-109) is under development for the treatment of obstructive sleep apnea. It is a fixed dose combination drug that is administered through oral route as capsule. The drug combination consists of norepinephrine reuptake inhibitor (NRI) atomoxetine and the antimuscarinic R-oxybutynin.
It was also under development for the treatment of snoring.
Apnimed overview
Apnimed is a biopharmaceutical company primarily focused on the development of pharmacological treatments for Obstructive Sleep Apnea (OSA) and related disorders. The company’s main activities involve conducting research and developing therapies that target the underlying neurobiological mechanisms causing airway obstruction in OSA. Apnimed’s lead product candidate is AD109, an oral pharmaceutical combination designed to treat OSA patients across a broad spectrum of disease severity. The company’s products are intended for patients suffering from OSA. The company’s products are being tested in clinical centers across the United States and Canada. Apnimed is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of AD-109’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
